Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hospital

RA Treatments Show Mixed Results

Thomas R. Collins  |  July 13, 2017

Highlights from the 2017 EULAR Congress MADRID—The anti-IL6 “nanobody,” vobarilizumab, produced mixed results when used with methotrexate (MTX), compared with MTX and placebo, according to results of a 24-week, double-blind Phase 2b study of patients with rheumatoid arthritis (RA), which were presented in an abstract session at the Annual European Congress of Rheumatology (EULAR). The…

Filed under:Biologics/DMARDsConditionsDrug UpdatesMeeting ReportsRheumatoid Arthritis Tagged with:EULAR

ARHP Clinical Focus Course Targets Management of Adults with SLE

Maura Iversen  |  July 13, 2017

This year the ARHP Clinical Focus Course brings together experts in the field to provide an interprofessional approach to the management of systematic lupus erythematosus (SLE) to improve patient outcomes. The daylong course, titled Systemic Lupus Erythematosus: Taming the Wolf—Salient Lessons from Practice and Research, which is offered on Nov. 4, will provide a case-based…

Filed under:ConditionsMeeting ReportsProfessional TopicsSystemic Lupus Erythematosus Tagged with:2017 ACR/ARHP Annual MeetingAssociation of Rheumatology Professionals (ARP)ClinicalEducationhealth professionalsinterprofessionalLupusManagementmultidisciplinarypatient carerheumatologistrheumatologySLETreatment

The ACR Board of Directors Adopts 5-Year Strategic Plan

Sharad Lakhanpal, MBBS, MD  |  July 13, 2017

Rheumatology is at a critical juncture in our history. To advance into the future, the ACR must thoroughly prepare for changing political landscapes, emerging technologies and workforce challenges. On May 12, the ACR Board of Directors met in Washington, D.C., to approve our ambitious new Strategic Plan for 2017–2022. This plan encompasses five strategic themes…

Filed under:Patient Perspective Tagged with:AC&RACR Board of DirectorsAmerican College of Rheumatology (ACR)Association of Rheumatology Professionals (ARP)futuregoalshealth professionalsLeadershipmissionrheumatologystrategic plan

How Global Geographic Disparities Affect Healthcare Outcomes

Simon M. Helfgott, MD  |  July 13, 2017

Your home & your health: Does geography impact medicine? Does it matter whether a region is surrounded by large bodies of water, encircled by towering mountain peaks or that its residents share a common ancestry? Consider Switzerland, a nation with a highly developed economy replete with advanced technological and medical infrastructure. Despite these advantages, less…

Filed under:OpinionRheuminationsSpeak Out Rheum Tagged with:cost of health careDiseaseDisparitiesgeographyglobalHealth InsuranceHealthcareInternationallife expectancymedicinepublic healthrheumatologyTechnology

Biophoto Associates / Science Source

A Stiff Man: A Case Study in Ankylosing Spondylitis

Charles Radis, DO  |  July 12, 2017

First Appearances I watched the old man, his back painfully bent, shuffle toward the scale. A blocky rigidity draped over him. His feet seemed stuck to the floor. His head hung heavily over his chest. Observing him from the end of the hallway, instead of a face, I saw only a mound of shaggy, matted…

Filed under:Axial SpondyloarthritisConditionsOther Rheumatic Conditions Tagged with:Ankylosing SpondylitisArthritisBack paincase reportClinicalDiagnosisManagementMedicationoffice visitpatient carerheumatologistrheumatologyspineTreatment

Opana ER Pulled from U.S. Market

Michele B. Kaufman, PharmD, BCGP  |  July 11, 2017

Endo Pharmaceuticals will work with the FDA to coordinate the organized removal of Opana ER from the U.S. market.

Filed under:AnalgesicsDrug Updates Tagged with:Drug SafetyOpana ERopioidOpioid abuse

Upadacitinib Meets Study Endpoints to Treat RA

Michele B. Kaufman, PharmD, BCGP  |  July 5, 2017

A recent clinical trial found that upadacitinib may effectively reduce disease activity at Week 12 for patients with moderate to severe rheumatoid arthritis…

Filed under:Drug Updates Tagged with:JAK inhibitorRheumatoid Arthritis (RA)upadacitinib

Changes in BMI Associated with Improvements in Disease Activity & Glucocorticoid Treatment

Arthritis Care & Research  |  July 4, 2017

A recent study examined the relationship between increased BMI and antineutrophil cytoplasmic antibody–associated vasculitis treatment with glucocorticoids. The results: Weight gain was independently associated with reductions in disease activity, increased glucocorticoid exposure and randomization to rituximab. The most significant increases in BMI occurred during the first six months of treatment, and newly diagnosed patients were more likely to experience an increase in BMI…

Filed under:ConditionsResearch RheumVasculitis Tagged with:ANCA-Associated VasculitisArthritis Care & ResearchBMIbody mass index (BMI)rituximabweight loss

Being Active May Reduce Risk of Chronic Low Back Pain

Shereen Lehman  |  June 30, 2017

(Reuters Health)—Regularly engaging in physical activity, from walking to intense exercise, may help to reduce the risk of chronic low back pain by, as much as 16%, according to a new review of previous studies. In the past, it hasn’t been clear whether physical activity staves off low back pain, or people without back pain…

Filed under:Soft Tissue Pain Tagged with:Back painExerciselow back painPainphysical activitywalking

Senate Republicans Unveil Obamacare Replacement Bill with Tough Debate Expected

Richard Cowan and Susan Cornwell  |  June 22, 2017

WASHINGTON (Reuters)—U.S. Senate Republicans on Thursday unveiled their version of legislation that would replace Obamacare, proposing to kill a tax on the wealthy that pays for it and reduce aid to the poor to cut costs. With Democrats deeply opposed to Republican attempts to overhaul former President Barack Obama’s signature healthcare law, the route to…

Filed under:Practice SupportProfessional Topics Tagged with:Obamacare replacement billSenate bill

  • « Previous Page
  • 1
  • …
  • 180
  • 181
  • 182
  • 183
  • 184
  • …
  • 323
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences